Department of Cardiothoracic Surgery, National Heart Center Singapore, Singapore 169609, Singapore.
National Heart Research Institute Singapore, National Heart Center Singapore, Singapore 169609, Singapore.
Cells. 2022 Jul 21;11(14):2257. doi: 10.3390/cells11142257.
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and is a fast progressive disease when left untreated. Identification of potential biomarkers in NSCLC is an ongoing area of research that aims to detect, diagnose, and prognosticate patients early to optimize treatment. We review the role of interleukin-11 (IL11), a stromal-cell derived pleiotropic cytokine with profibrotic and cellular remodeling properties, as a potential biomarker in NSCLC. This review identifies the need for biomarkers in NSCLC, the potential sources of IL11, and summarizes the available information leveraging upon published literature, publicly available datasets, and online tools. We identify accumulating evidence suggesting IL11 to be a potential biomarker in NSCLC patients. Further in-depth studies into the pathophysiological effects of IL11 on stromal-tumor interaction in NSCLC are warranted and current available literature highlights the potential value of IL11 detection as a diagnostic and prognostic biomarker in NSCLC.
非小细胞肺癌 (NSCLC) 占肺癌的 85%，如果不治疗，病情会迅速恶化。识别 NSCLC 中的潜在生物标志物是一个正在进行的研究领域，旨在早期发现、诊断和预测患者，以优化治疗。我们回顾了白细胞介素 11 (IL11) 的作用，IL11 是一种源自基质细胞的多功能细胞因子，具有促纤维化和细胞重塑特性，是 NSCLC 潜在的生物标志物。本综述确定了 NSCLC 生物标志物的需求、IL11 的潜在来源，并利用已发表的文献、公开数据集和在线工具总结了现有信息。我们发现越来越多的证据表明 IL11 可能是 NSCLC 患者的潜在生物标志物。需要进一步深入研究 IL11 在 NSCLC 中对基质-肿瘤相互作用的病理生理影响，目前的文献强调了 IL11 检测作为 NSCLC 诊断和预后生物标志物的潜在价值。
Zotero 插件